Mylan (NSDQ:MYL) acquired global development and marketing rights to a fast-acting, non-opioid pain relief drug formulated by Prayog Labs, the company announced today.
The pharma giant is positioning the medication, Meloxicam, as a non-addictive treatment option for patients experiencing acute pain following dentistry procedures or following a surgery.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan acquires fast-acting, non-opioid painkiller appeared first on MassDevice.